The ADDF's mission is to accelerate the discovery of drugs to prevent, treat, and cure Alzheimer's, other dementias, and cognitive aging by funding breakthrough research in …

The ADDF focuses on translating the knowledge we have gained about the causes of Alzheimer's disease – known as the “biology of aging” – into drugs to conquer it.

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias.

Under her leadership, ADDF leverages venture philanthropy, global collaboration, and scientific rigor to catalyze breakthroughs and drive the next era of precision medicine for Alzheimer’s …

Bill Gates and ADDF Co-Founder Leonard A. Lauder partnered to adopt a new approach that brings together philanthropic capital with a venture mindset to advance bold ideas for easier, …

This study, supported by the ADDF and initially presented in 2020, adds to the growing body of evidence that GLP-1 drugs are a promising pathway for the treatment and prevention of …

Board members includes leaders from government, industry and the research community, who serve as ambassadors for the ADDF and provide strategic oversight and counsel.

Through the PACT program, the ADDF funds the early phases of clinical trials for novel drugs to treat Alzheimer's disease and related dementias.

The ADDF supports one of the largest and most diverse clinical development portfolios for Alzheimer’s disease, with over 30 active clinical trials that span multiple drug targets.

Our 2024 Annual Report highlights how the ADDF is advancing novel therapeutics, better ways to diagnose Alzheimer's and methods to prevent this disease.